NCT06336213 Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients
| NCT ID | NCT06336213 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Petrovsky National Research Centre of Surgery |
| Condition | Aortic Aneurysm and Dissection |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-01-23 |
| Primary Completion | 2026-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-01-23 with a primary completion date of 2026-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.
Eligibility Criteria
Inclusion Criteria: Thoracic aorta aneurysm/dissection Exclusion Criteria: Blood sample hemolysis
Contact & Investigator
Boris Akselrod, Professor
PRINCIPAL INVESTIGATOR
Petrovsky NRCS
Frequently Asked Questions
Who can join the NCT06336213 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Aortic Aneurysm and Dissection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06336213 currently recruiting?
Yes, NCT06336213 is actively recruiting participants. Contact the research team at gubko@artvig.ru for enrollment information.
Where is the NCT06336213 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT06336213 clinical trial?
NCT06336213 is sponsored by Petrovsky National Research Centre of Surgery. The principal investigator is Boris Akselrod, Professor at Petrovsky NRCS. The trial plans to enroll 50 participants.